tbuckley/cabot-search huggingface dataset:
Updated results from a randomized multicenter trial of DVd vs VAd in patients with newly diagnosed multiple myeloma
Authors: R. M. Rifkin, M. A. Hussein, S. A. Gregory, A. Mohrbacher
Journal: Journal of Clinical Oncology (2004)

6509 Background: Pegylated liposomal doxorubicin (Doxil/Caelyx) was used as a replacement for conventional doxorubicin in the VAd regimen to improve the safety profile. Methods: This multicenter randomized trial compared the efficacy and safety of DVd (pegylated liposomal doxorubicin 40 mg/m2 and vincristine 1.4 mg/m2 [max 2.0 mg/m2] IV on Day 1, and reduced-dose dexamethasone 40 mg PO on Days 1–4) with VAd (vincristine 0.4 mg/day and conventional doxorubicin 9 mg/m2/day by continuous IV infusion on Days 1–4 and dexamethasone 40 mg PO on Days 1–4) in patients with newly diagnosed multiple myeloma. Treatment was repeated every 4 weeks until transplantation, disease progression, stable plateau disease, or unacceptable toxicity. Primary endpoints were objective response and clinical benefit (defined as reduced hospitalization due to adverse events, documented sepsis, antibiotic use, and grade 3/4 neutropenia or neutropenic fever). Results: Patient demographics were similar for both groups. Safety and efficacy data for 175/198 patients are included. Objective response was similar for DVd and VAd patients (44% vs 39%, respectively). The number of patients proceeding to transplantation (DVd 36% vs VAd 34%) and the number of successful transplantations (93% for both) were similar. The benefits of DVd vs VAd included a significant decrease in grade 3/4 neutropenia (8% vs 23%, P<.05), a decrease in need for central venous access, a lower incidence of documented sepsis, less antibiotic treatment required, fewer days of hospitalization due to adverse events, fewer cycles administered in the hospital, and fewer hospital and clinic visits for drug administration. Patients receiving DVd had significantly less alopecia (20% vs 44%, P<.001) but more hand-foot syndrome (HFS, 25% vs 1%, P<.001); however, grade 3/4 HFS was minimal (3% vs 0%). Conclusion: Pegylated liposomal doxorubicin as a replacement for conventional doxorubicin in the VAd regimen has similar efficacy and several clinical advantages in newly diagnosed multiple myeloma, including significantly less neutropenia, alopecia, and fewer hospital and clinic visits for drug administration. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Ortho Biotech Products, L.P. Ortho Biotech Products, L.P.
Assesment of SOX-17 gene promoter hypermethylation in hepatocellular carcinoma.
Authors: Leonidas Chelis, Ioanna Balgouranidou, Triantafyllia Koukaki, Prodromos Michailidis, Evagelos Christakidis, Nikolaos Xenidis, Kiriakos Amarantidis, Grigorios Trypsianis, Stylianos Kakolyris
Journal: Journal of Clinical Oncology (2013)

e15063 Background: SRY-box containing gene 17 (SOX-17) is implicated in the WNT/β-catenin pathway and acts as a tumor suppressor gene inhibiting the transcription of activated β-catenin. WNT oncogene plays a crucial role in liver carcinogenesis and has been shown to correlate with poor survival and aggressive behavior in hepatocellular carcinoma (HCC). Silencing of SOX-17 gene through promoter hypermethylation results in WNT overexpression. Tumor-related cell free DNA (cfDNA), circulating in the blood of cancer patients can be used for the detection of methylation status of several genes. Therefore, we examined SOX-17 methylation in the blood of HCC patients and correlated it with the outcome. Methods: Patients diagnosed with HCC were eligible. cfDNA from 87 patients (N=87) was isolated from 200 μL serum before any treatment. After DNA extraction, all samples were subjected to a sodium bisulfite conversion reaction. Methylation specific polymerase reaction (MSP) for SOX17 promoter methylation was performed using specific primer pairs for both the methylated and unmethylated promoter sequences. Results: According to BCLC staging system, our patients were staged as A=5 (5.6%), B=15 (17.2%), C=67 (77%) respectively. SOX-17 methylation was detected in 58 (66.7%) patients while 29 (33.3%) had a non-methylated gene. The methylated form of the gene was significantly correlated with an impaired performance status (PS) of 2-4 (p=0.021) and with extrahepatic spread of the disease (p=0.036). No correlation was detected for stage, Child-Pough score of cirrhosis, or underlying cause of HCC. The overall survival (OS) was 14 months for the non-methylated and 5 months for the methylated gene, respectively (p= 0.0062). Sixty three patients received sorafenib as 1 st line treatment. The OS was 15 months for patients with the non-methylated and 6 months for patients with the methylated gene, respectively (p= 0.012). In the multivariate analysis for OS, SOX-17 methylation status along with PS remained significant (p=0.04) Conclusions: Assessment of SOX-17 promoter hypermethylation in the peripheral blood is feasible. SOX-17 gene methylation is a frequent event in HCC and seems to correlate with a poorer outcome.
Prevalence of cancer-related fatigue in a population-based sample of colorectal, breast, and prostate cancer survivors.
Authors: Jennifer M Jones, Doris Howell, Karin Lou Olson, Haiyan Jiang, Charles N Catton, Pamela Catton, Neil Eric Fleshner, David R. McCready, Rebecca Wong, Melania Pintilie, Mihaela Dirlea, Monika K. Krzyzanowska
Journal: Journal of Clinical Oncology (2012)

9131 Background: Cancer-related fatigue (CRF) is the most prevalent and distressing cancer-related symptom and has a greater negative impact on patients' daily activities and quality of life than other cancer-related symptoms, including pain and depression. However, the prevalence and severity of persistent CRF and related disability in the post-treatment survivorship period has seldom been examined in populations other than breast cancer. The primary objective of the study was to describe the prevalence of significant CRF and associated levels of disability in a mixed cancer population sample at 3 time points in the post-treatment survivorship trajectory. Methods: Based on cancer registry data, a self-administered mail based questionnaire using Dillman's Tailored Design Method was sent to 3 cohorts of disease-free cancer survivors (6-18 months; 2-3 years; and 5-6 years post-treatment) previously treated for non-metastatic breast, prostate or colorectal cancer. Fatigue was measured using the FACT-F and disability was measured with the WHO-Disability Assessment Schedule. Clinical information was extracted from chart review. Frequencies of significant fatigue by disease sites and time points were studied and compared using chi-square test. Disability between those with and without CRF was also compared using Cochran-Armitage trend test. Results: 1294 questionnaire packages were completed (63% response rate). The FACT-F score was 39.1+10.9; 29% (95% CI: [27%, 32%]) of the sample reported significant fatigue (FACT-F≤34) and this was associated with much higher levels of disability (p&lt;0.0001). Breast (40% [35%, 44%]) and colorectal (33% [27%, 38%]) survivors had significantly higher rates of fatigue (≤34) compared to the prostate group (17% [14%, 21%]) (p&lt;0.0001). Fatigue levels remained relatively stable across the 3 time points. Conclusions: CRF was a significant and debilitating symptom for a substantial minority of the respondents across all 3 time points. Effective CRF management strategies are needed and have the potential to significantly reduce morbidity associated with cancer and its treatments and to improve quality of life for the growing population of cancer survivors.
Safety and Tolerability of Obinutuzumab (GA101) with Shorter Duration of Infusion in Japanese Patients with Previously Untreated CD20-Positive B-Cell Non-Hodgkin's Lymphoma (NHL)-Comparison with GAO4915g (GATHER) and BO21005 (GOYA) Studies
Authors: Hideki Tsujimura, Kyoya Kumagai, Takanori Teshima, Kiyohiko Hatake, Koji Izutsu, Kiyoshi Ando, Tomohiro Kinoshita, Takayuki Ishikawa, Koji Kato, Eisuke Ueda, Kiyohiko Nakai, Hiroshi Kuriki, Kensei Tobinai
Journal: Blood (2016)
PREDICTIVE VALUES OF THE IDEAL CARDIOVASCULAR HEALTH AND THE FUSTER-BEWAT SCORES FOR DETECTING SUBCLINICAL ATHEROSCLEROSIS IN HEALTHY INDIVIDUALS
Authors: Juan Miguel Fernández-Alvira, Stuart Pocock, Antonio Fernández-Ortiz, Borja Ibañez, Rodrigo Fernández-Jiménez, Javier Sanz, Leticia Fernández-Friera, Valentin Fuster, Héctor Bueno
Journal: Journal of the American College of Cardiology (2017)
Molecular classification of diffuse cerebral gliomas using genome- and transcriptome-wide profiling.
Authors: Michael Weller, Ruthild Weber, Edith Willscher, Vera Riehmer, Bettina Hentschel, Markus Kreuz, Joerg Felsberg, Ulrike Beyer, Henry Loeffler-Wirth, Kerstin Kaulich, Dorothee Gramatzki, Manfred Westphal, Gabriele Schackert, Matthias Simon, Joerg Tonn, Torsten Pietsch, Markus Loeffler, Andreas von Deimling, Hans Binder, Guido Reifenberger
Journal: Journal of Clinical Oncology (2015)

2007 Background: WHO grade II and III cerebral gliomas represent a major challenge for histological classification and clinical management. Here, we aimed to improve prognostically relevant patient stratification by characterizing genomic and transcriptional profiles in a prospective patient cohort of the German Glioma Network. Methods: We performed microarray-based genome- and transcriptome-wide molecular profiling of primary tumor samples from 137 patients with cerebral gliomas. Integrative bioinformatic analyses were employed to define molecular subgroups, which were then related to histology, molecular biomarkers, including isocitrate dehydrogenase 1 or 2 (IDH1/2) mutation, 1p/19q co-deletion and telomerase reverse transcriptase (TERT)promoter mutations, and patient outcome. Results: Genomic profiling identified five distinct glioma groups, including three IDH1/2 mutant and two IDH1/2 wild-type groups. Expression profiling revealed eight transcriptionally different tumor groups (five IDH1/2 mutant, three IDH1/2 wild-type), which were only partially linked to the genomic groups. Correlation of DNA-based molecular stratification withoutcome allowed for the definition of three major prognostic groups with characteristic genomic aberrations. The best prognosis was found in patients with IDH1/2 mutant and 1p/19q co-deleted tumors. Patients with IDH1/2 wild-type gliomas and glioblastoma-like genomic alterations, including gain of chromosome arm 7q (+7q), loss of chromosome arm 10q (-10q), TERT promoter mutation and oncogene amplification, displayed the worst outcome. Intermediate survival was seen in patients with IDH1/2 mutant but 1p/19q intact, mostly astrocytic gliomas, and in patients with IDH1/2 wild-type gliomas lacking the +7/-10q genotype and TERT promoter mutation. Conclusions: DNA-based molecular subgrouping stratified patients into prognostically distinct groups better than histological classification, whereas addition of gene expression data did not further improve prognostic stratification.
IATROGENIC DIVERSION OF INFERIOR VENA CAVA TO LEFT ATRIUM AFTER SURGICAL CLOSURE OF ATRIAL SEPTAL DEFECT
Authors: Aditi Singhvi, Arun Agarwal, Jonathan Hammond, Immad Sadiq, Shailendra Upadhyay, Konstadina Darsaklis
Journal: Journal of the American College of Cardiology (2017)
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ALIROCUMAB IN HIGH CARDIOVASCULAR RISK PATIENTS WITH HYPERCHOLESTEROLEMIA NOT ADEQUATELY CONTROLLED WITH THEIR LIPID-MODIFYING THERAPY IN SOUTH KOREA AND TAIWAN
Authors: Kwang K. Koh, Chang-Wook Nam, Ting-Hsing Chao, Ming-En Liu, Chiung-Jen Wu, Dong-Soo Kim, Chong-Jin Kim, Ivy Li, Jianyong Li, Marie Baccara-Dinet, Pi-Jung Hsiao, Chern-En Chiang
Journal: Journal of the American College of Cardiology (2017)
FRAIL OLDER PATIENTS HAVE A GREATER IMPROVEMENT IN PHYSICAL QUALITY OF LIFE THAN ROBUST PATIENTS AT ONE YEAR FOLLOWING INVASIVE TREATMENT FOR NON-ST ELEVATION ACUTE CORONARY SYNDROME
Authors: Vijayalakshmi Kunadian, Hannah Sinclair, Jonathan Batty, Sophie Z. Gu, Benjamin Beska, Murugapathy Veerasamy, Gary A. Ford, Weiliang Qiu
Journal: Journal of the American College of Cardiology (2017)
Multivariate analysis of expression of the microtubule-associated protein, tau, predicts improved progression free and overall survival in patients with metastatic HER-2-negative breast cancers treated with docetaxel and vinorelbine plus filgrastim
Authors: A. M. Gown, L. C. Goldstein, P. L. Porter, R. B. Livingston, S. Tam, I. Yeh, W. E. Barlow, J. R. Gralow, D. F. Hayes
Journal: Journal of Clinical Oncology (2006)

543 Background: Drugs that poison the mitotic spindle, including taxanes and vinca alkaloids, are active agents against breast cancer. Preliminary evidence showed that high expression levels of tau predicted improved PFS and OS in patients with metastatic HER-2-negative breast cancers treated with docetaxel and vinorelbine plus filgrastim. We now tested whether levels of tau and another microtubule associated protein, beta-tubulin, could predict PFS and OS in multivariate analysis using other prognostic marker studies, including ER, PR, p53 and Ki-67 on a tissue microarray (TMA) obtained from patients in the SWOG S0102 trial. Materials and Methods: Immunohistochemistry (IHC) using antibodies to tau, beta-tubulin, ER, PR, p53, and Ki-67 was performed on a TMA constructed from the S0102 paraffin blocks. All markers were scored semiquantitatively from 0 to 3. Progression free survival (PFS) and overall survival (OS) were evaluated using multivariate analysis. Results: A total of 38 patients (41.3%) were evaluated. Tau was positively correlated with ER (r=0.36; p=0.0325) and PR (r=0.63; p&lt;0.0001), but not with beta tubulin (p=0.34), Ki-67 (p=0.58), or age (p=0.73). Beta tubulin was not significantly correlated with any other markers. Adjusting for age, there was a significant effect of tau expression on OS (HR=0.667, p= 0.0193) and PFS (HR=0.653; p=0.0035), with higher tau associated with longer survival. When adjusted for both age and PR, there was a marginally significant effect of tau on OS (HR=0.582; p=0.056) and PFS (HR=0.604; p= 0.065). Beta tubulin was not associated with OS (HR=0.909; p=0.66) and PFS (HR=0.904; p=0.58) adjusted for age. Conclusions: In multivariate analysis, identification of breast cancer specimens showing high expression levels of tau predicts improved PFS and OS in patients with metastatic HER-2-negative breast cancers treated with docetaxel and vinorelbine plus filgrastim. High expression of tau also correlated with PR and ER expression. These results confirm and expand earlier studies of the predictive power of tau in a multivariate analysis using a panel of IHC markers for breast cancer. No significant financial relationships to disclose.
INSULIN RESISTANCE ASSOCIATES WITH ADVERSE CARDIAC REMODELING IN THE ABSENCE OF HYPERTENSION IN YOUNG SOUTH ASIANS
Authors: Rupan Bose, Millie Arora, Fahim Abbasi, Esha Roy, Shriram Nallamshetty, Abha Khandelwal, Prajakta Ranade, Rajesh Dash
Journal: Journal of the American College of Cardiology (2017)
A phase IIb trial of coix seed injection for advanced pancreatic cancer.
Authors: Mary Ann Tagliaferri, Lee Steven Schwartzberg, Michael M. Chen, Luis H. Camacho, Edward H. Kaplan, Francis P. Arena, Bryan J. Bienvenu, Susan E. North, Hermant Patel, Dapeng Li
Journal: Journal of Clinical Oncology (2013)

e15023 Background: Kanglaite injection (KLTi) is a purified botanical extract injection tested for pancreatic cancer. KLTi is derived from Coix seed of the plant Coix lacrama-jobi. KLTi demonstrated growth inhibitory effects in vitro. In xenograft models with PANC-1 cell lines in BALB/C mice, KLTi combined with gemcitabine had synergistic tumor inhibitory activity greater than gemcitabine alone. KLTi is approved and widely used in China to treat non-small cell lung cancer and primary liver cancer. We report final cohort 1 results from a US phase 2b clinical trial. Methods: Eligible patients with histologically confirmed unresectable pancreatic cancer were randomized to a regimen of either KLTi 30g/day plus a standard course of gemcitabine or a standard course of gemcitabine only. The two groups were compared in efficacy, measure by progression-free survival (PFS), and safety. Results: Forty-one patients were randomized to cohort 1 and 38 patients received treatment: 26 received KLTi plus gemcitabine, 12 received gemcitabine only, and 3 received no treatment. The KLTi plus gemcitabine group had a median PFS of 114 days, significantly longer than the median PFS of 57.5 days in the gemcitabine only group (HR 0.338, 95% CI: 0.145, 0.788, p=0.008). The overall response rates were 15.5% (4/26) and 8.3% (1/12) for KLTi plus gemcitabine and gemcitabine only, respectively. Two serious adverse events were possibly related to KLTi; one subject had a pulmonary embolism and the other experienced transient confusion. The adverse events were similar between the groups and consistent with gemcitabine toxicities. Conclusions: Combined with gemcitabine, KLTi injection showed favorable tolerability and encouraging clinical activity for the treatment of advanced pancreatic cancer. Clinical trial information: NCT00733850.
The Clinical Significance of Biphenotypia in Blastic Phase CML.
Authors: Constantine S. Tam, Hagop M. Kantarjian, Srdan Verstovsek, William G. Wierda, Jenny Shan, Joselle Otero-Palacios, Ahmed Awais, Farhad Ravandi-Kashani, Jorge Cortes
Journal: Blood (2006)
TRIB2 Gene Overexpression Is Associated with Adult Minimally Differentiated Acute Myeloid Leukemia
Authors: Crescenzio Francesco Minervini, Valentina Buttiglione, Nicoletta Coccaro, Luciana Impera, Luisa Anelli, Antonella Zagaria, Paola Casieri, Angela Minervini, Giuseppina Tota, Francesco Albano, Giorgina Specchia
Journal: Blood (2011)
DECREASED HEART RATE VARIABILITY IS ASSOCIATED WITH INCREASED CARDIAC IRON DEPOSIT DETERMINED BY CARDIAC T2* MRI AND DECREASED LEFT VENTRICULAR FUNCTION IN TRANSFUSION DEPENDENT THALASSEMIA PATIENTS
Authors: Sintip Pattanakuhar, Arintaya Phrommintikul, Adisak Tantiworawit, Sasikarn Konginn, Somdej Srichairattanakool, Siriporn Chattipakorn, Nipon Chattipakorn
Journal: Journal of the American College of Cardiology (2017)
HOW USEFUL IS 99MTC-DPD SCINTIGRAPHY IN DIAGNOSIS OF CARDIAC AMYLOIDOSIS IN TRANSTHYRETIN V30M FAMILIAL AMYLOID POLYNEUROPATHY?
Authors: Maria C. Azevedo Coutinho, Nuno Cortez-Dias, Susana Gonçalves, Guilhermina Cantinho, Tatiana Guimarães, Gustavo Lima da Silva, Ana R. Francisco, Laura Santos, Isabel Conceição, Fausto Pinto
Journal: Journal of the American College of Cardiology (2017)
G-PROTEIN RECEPTOR KINASE 5 POLYMORPHISMS AND OUTCOMES IN THE AFRICAN AMERICAN HEART FAILURE TRIAL: RESULTS FROM THE GENETIC RISK ASSESSMENT OF HEART FAILURE IN AFRICAN-AMERICANS SUB-STUDY
Authors: Amber E. Johnson, Karen Hanley-Yanez, Clyde Yancy, Anne Taylor, Arthur Feldman, Dennis McNamara
Journal: Journal of the American College of Cardiology (2017)
Clinical Relevance of Driver Mutations and Number of Driver Mutations in Patients with Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
Authors: Guillermo Montalban-Bravo, Koichi Takahashi, Feng Wang, Marina Konopleva, Song Xingzhi, Graciela M. Nogueras-Gonzalez, Xuelin Huang, Ana Alfonso Pierola, Elias J. Jabbour, Simona Colla, Gautam Borthakur, Naval Daver, Courtney D. DiNardo, Zeev Estrov, Tapan M. Kadia, Naveen Pemmaraju, Farhad Ravandi, Carlos E Bueso-Ramos, Ali N. Chamseddine, Jianhua Zhang, Hagop M. Kantarjian, Keyur Patel, Lynda Chin, Andrew Futreal, Guillermo Garcia-Manero
Journal: Blood (2016)
Development of brain metastases in stage III/IV non-small cell lung cancer patients treated with or without erlotinib.
Authors: Jing Liu, Li Kong, Xue Meng, Jinbo Yue, Xindong Sun, Jinming Yu
Journal: Journal of Clinical Oncology (2013)

e19011 Background: Non-small cell lung cancer (NSCLC) has a risk of death from brain metastases (BM) that exceeds potential mortality from extracranial disease progression. Erlotinib has been proved to be effective for NSCLC patients. We hold a study to evaluate value of erlotinib in preventing BM in stage III/IV NSCLC patients. Methods: Pathologically confirmed NSCLC stage III/IV patients were included and divided into erlotinib group and control group according to whether erlotinib administration (at least one month) in 1- or 2-line therapy or not. Stage IV patients with BM were excluded. Patients with any EGFR-TKI treatment were excluded from control group. Times of erlotinib administration to BM and to death or last follow-up were recorded for erlotinib group. Times of corresponding 1- or 2-line chemotherapy to BM and to death or last follow-up were recorded for control group correspondingly. Time to BM, 1- and 2-year incidence of BM were end points. Results: 140 patients were included (68 in erlotinib group and 72 in control group) and all clinical characteristics between two groups were balanced. At a median follow-up of 20.0 months, the median time to BM for all patients was 28.0 months (95% CI, 23.795-32.205 months). 1- and 2-year incidence of BM were 17.8% (95% CI, 10.744-24.856%) and 38.8% (95% CI, 27.236-50.364%) respectively. The median time to BM were 42.0 months (95% CI, 15.567-68.433 months) and 19.0 months (95% CI, 11.305-26.695 months) (P=0.028) for erlotinib group and control group. Erilotinib group has a lower BM incidence than control group (1-year: 14.4%, 95% CI: 4.992%-23.808%, vs 21.1%, 95% CI: 10.712%-31.488%, P=0.384; 2-year: 26.2%, 95% CI: 18.712%-33.688%, vs 50.2%, 95% CI: 34.128%-66.272%, P=0.005). Multivariate analysis shows interval to BM were longer for erlotinib group (HR, 2.531; 95% CI, 1.272-5.051; P=0.008) and stage III disease (HR, 2.093; 95% CI, 1.035-4.231; P=0.040). Conclusions: Erlotinib administration improves time to BM and 2-year incidence of BM of stage III/IV NSCLC patients. Erlotinib administration and stage III disease predicts lower incidence of BM in all patients.
Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling
Authors: Alexa B. Schrock, Shuyu D. Li, Garrett M. Frampton, James Suh, Eduardo Braun, Ranee Mehra, Steven C. Buck, Jose A. Bufill, Nir Peled, Nagla Abdel Karim, K. Cynthia Hsieh, Manuel Doria, James Knost, Rong Chen, Sai-Hong Ignatius Ou, Jeffrey S. Ross, Philip J. Stephens, Paul Fishkin, Vincent A. Miller, Siraj M. Ali, Balazs Halmos, Jane J. Liu
Journal: Journal of Thoracic Oncology (2017)